Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients

被引:17
作者
Zhang, Tao [1 ]
Sun, Dan [1 ]
Shu, Zuocheng [1 ]
Duan, Ziyun [2 ]
Liu, Yang [1 ]
Du, Qian [1 ]
Zhang, Ying [1 ]
Dong, Yuzhu [1 ]
Wang, Taotao [1 ]
Hu, Sasa [1 ]
Cheng, Hua [2 ]
Dong, Yalin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Pharm, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Pharm, Affiliated Children Hosp, Xian, Peoples R China
关键词
teicoplanin; pediatrics; population pharmacokinetics; dosing optimization; Monte Carlo simulation; STAPHYLOCOCCUS-AUREUS; PHARMACODYNAMICS; CLEARANCE; CHILDREN; EFFICACY; PLASMA;
D O I
10.3389/fphar.2020.594562
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The pharmacokinetics (PK) of teicoplanin differs in children compared with adults. Our aim was to determine the PK of teicoplanin in an Asian pediatric population and to optimize dosage regimens. Methods: This was a retrospective PK study and all the data were collected from hospitalized children. We developed a population PK model using sparse data, and Monte Carlo simulation was used to assess the ability of standard teicoplanin regimen and other different dosage regimens. The optimal dosing regimens were defined as achieving the target trough concentration (C (min)) of 10 mg/L and pharmacokinetic/pharmacodynamic (PK/PD, [AUC(24)/MIC]) of 125 for moderate infection. For severe infection, the optimal dosing regimens were defined as achieving the target 15 mg/L and AUC(24)/MIC of 345. Results: 159 children were included and 1.5 samples/children on average were provided. Estimated clearance of teicoplanin was 0.694 L/h (0.784/L/h/70 kg) and volume of distribution was 1.39 L. Teicoplanin standard loading dose was adequate for moderate infection, while 13 mg/kg was needed for severer infection. With standard maintenance doses, both patients with moderate and severe infection failed to achieve the target C (min). 12 and 16 mg/kg/day were required to achieve a C (min) >= 10 and 15 mg/L, respectively. However, standard maintenance dose was adequate to achieve AUC(24)/MIC >= 125 for moderate infection, and 12 mg/kg/day was needed to achieve AUC(24)/MIC >= 345 for severe infection. Lower weight and serum creatinine were associated with higher dose. Conclusion: Optimal doses based on the target C (min) were higher than that based on the PK/PD target. To achieve the C (min) and PK/PD targets simultaneously, a standard loading dose was adequate for moderate infection based on simulation, while dosing higher than standard doses were required in other situation. Further clinical studies with rich sampling from children is required to confirm our findings.
引用
收藏
页数:12
相关论文
共 49 条
[1]   Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children [J].
Aarons, L ;
Rowland, M ;
Khan, A ;
Taborelli, G ;
Ferrea, G ;
Tarantino, V ;
Fioredda, F ;
Rosina-Parenti, R ;
Cavenaghi, L ;
Borgonovi, M .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) :265-270
[2]   Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever [J].
Ahn, Byung-Jin ;
Yim, Dong-Seok ;
Lee, Dong-Gun ;
Kwon, Jae-Cheol ;
Kim, Si-Hyun ;
Choi, Su-Mi .
YONSEI MEDICAL JOURNAL, 2011, 52 (04) :616-623
[3]   Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis [J].
Brink, A. J. ;
Richards, G. A. ;
Cummins, R. R. ;
Lambson, J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (05) :455-458
[4]  
British Medical Association Royal Pharmaceutical Society Royal College of Paediatrics and Child Health Neonatal and Paediatric Pharmacists Group, 2015, BRIT NAT FOR CHILDR, P289
[5]   Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy [J].
Byrne, C. J. ;
Roberts, J. A. ;
McWhinney, B. ;
Ryder, S. A. ;
Fennell, J. P. ;
O'Byrne, P. ;
Deasy, E. ;
Egan, S. ;
Desmond, R. ;
Enright, H. ;
D'Arcy, D. M. ;
McHugh, J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (09) :674.e7-674.e13
[6]   Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy [J].
Byrne, Catherine J. ;
Parton, Ted ;
McWhinney, Brett ;
Fennell, Jerome P. ;
O'Byrne, Philomena ;
Deasy, Evelyn ;
Egan, Sean ;
Enright, Helen ;
Desmond, Ronan ;
Ryder, Sheila A. ;
D'Arcy, Deirdre M. ;
McHugh, Johnny ;
Roberts, Jason A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (04) :995-1003
[7]   Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity [J].
Byrne, Catherine J. ;
Egan, Sean ;
Fennell, Jerome P. ;
O'Byrne, Philomena ;
Enright, Helen ;
Deasy, Evelyn ;
Ryder, Sheila A. ;
D'Arcy, Deirdre M. ;
McHugh, Johnny .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 46 (04) :406-412
[8]   Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen [J].
Cazaubon, Yoann ;
Venisse, Nicolas ;
Mimoz, Olivier ;
Maire, Pascal ;
Ducher, Michel ;
Bourguignon, Laurent ;
Goutelle, Sylvain .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (10) :2804-2812
[9]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[10]   The use and therapeutic drug monitoring of teicoplanin in the UK [J].
Darley, ESR ;
MacGowan, AP .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (01) :62-69